Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ 17,010 $ 7,743 $ 46,137 $ 25,194
General and administrative 5,179 3,907 16,936 11,535
Total operating expenses 22,189 11,650 63,073 36,729
Loss from operations (22,189) (11,650) (63,073) (36,729)
Other income (expense), net:        
Interest income 29 229 140 1,494
Interest expense (522) 0 (522) 0
Total other income (expense), net (493) 229 (382) 1,494
Net loss (22,682) (11,421) (63,455) (35,235)
Other comprehensive (loss) income:        
Unrealized (loss) gain on marketable securities (2) (104) (9) 2
Total other comprehensive (loss) income (2) (104) (9) 2
Comprehensive loss $ (22,684) $ (11,525) $ (63,464) $ (35,233)
Basic and diluted net loss per common share $ (0.33) $ (0.17) $ (0.92) $ (0.51)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share 69,022,937 68,887,092 68,985,112 68,884,894